JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Hutchison China MediTech Ltd ADR

Fermé

SecteurSoins de santé

17.59 -0.79

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.59

Max

17.66

Chiffres clés

By Trading Economics

Revenu

6M

Ventes

162M

P/E

Moyenne du Secteur

88.7

38.156

Marge bénéficiaire

3.676

Employés

1,811

EBITDA

-5M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+21.24% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3B

Ouverture précédente

18.38

Clôture précédente

17.59

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 juil. 2025, 17:53 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 juil. 2025, 15:58 UTC

Résultats
Principaux Mouvements du Marché

Aon Shares Rise After 2Q Earnings Beat

25 juil. 2025, 15:08 UTC

Principaux Mouvements du Marché

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 juil. 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 juil. 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 juil. 2025, 20:40 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 20:10 UTC

Résultats

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 19:56 UTC

Résultats

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 juil. 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 juil. 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 juil. 2025, 19:01 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 juil. 2025, 17:38 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 juil. 2025, 17:13 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 16:46 UTC

Résultats

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 juil. 2025, 16:45 UTC

Résultats

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 juil. 2025, 16:27 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 juil. 2025, 16:02 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 juil. 2025, 15:34 UTC

Résultats

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 juil. 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 juil. 2025, 15:05 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 juil. 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 juil. 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 juil. 2025, 14:36 UTC

Market Talk
Résultats

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

21.24% hausse

Prévisions sur 12 Mois

Moyen 21.35 USD  21.24%

Haut 28 USD

Bas 14.7 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

14.24 / 14.78Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.